CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Recruiting

Phase 1

Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05442515

Conditions

B-NHL

B-Non Hodgkin Lymphoma

Acute Lymphocytic Leukemia

Acute Lymphoblastic Leukemia

B-precursor ALL

Eligibility Criteria

Sex: All

Age: 3 - 39

Healthy Volunteers: Not accepted

Interventions

CD19/CD22-CAR-transduced T cells

cyclophosphamide

fludarabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-31.